Literature DB >> 9513871

c-myc, c-erbB-2, c-fms and bcl-2 oncoproteins. Expression in normal placenta, partial and complete mole, and choriocarcinoma.

V Fulop1, S C Mok, D R Genest, I Szigetvari, I Cseh, R S Berkowitz.   

Abstract

OBJECTIVE: To determine the expression of bcl-2, c-myc, c-fms and c-erbB-2 oncoproteins in normal placentas, partial and complete hydatidiform moles, and choriocarcinomas and to examine the possible presence of mutations in the K-ras gene in complete moles and choriocarcinomas. STUDY
DESIGN: The expression of the above oncoproteins was determined immunohistochemically by specific antibodies for these proteins on formalin-fixed paraffin sections of 18 normal placentas, 17 partial moles, 25 complete moles and 11 choriocarcinomas. This was followed by polymerase chain reaction analysis (exons 12 and 13) of K-ras gene for possible mutations in complete moles and choriocarcinomas.
RESULTS: Expression of c-fms oncoprotein appeared confined to the cytoplasm of syncytiotrophoblastic cells. The c-fms protein staining intensity of the syncytiotrophoblastic layer showed no significant difference among the four gestational tissues. c-erbB-2 antibody expression was confined to the cellular membrane of the extravillous trophoblast. When compared with normal placenta or partial mole, the expression of c-erbB-2 protein was significantly stronger in complete mole (P < .0001 and P < .0001, respectively) and choriocarcinoma (P < .0001 and P < .0001, respectively). Expression of bcl-2 protein was significantly stronger in the syncytiotrophoblast in complete mole and choriocarcinoma as compared to both normal placenta and partial mole (P < .0001 and P < .0001, respectively). Staining of c-myc of the syncytiotrophoblastic layer was significantly stronger in placenta, complete mole and choriocarcinoma than in partial mole (P < .0001, P < .0001 and P < .0001, respectively). Mutation in K-ras gene was not found in any of the 22 complete moles or 11 choriocarcinomas examined.
CONCLUSION: Our data suggest that c-myc, c-erbB-2, c-fms and bcl-2 oncoproteins may be important in the pathogenesis of complete mole and choriocarcinoma. However, while both complete mole and choriocarcinoma were characterized by overexpression of c-myc, c-erbB-2 and bcl-2, partial mole generally did not strongly express these three oncoproteins.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9513871

Source DB:  PubMed          Journal:  J Reprod Med        ISSN: 0024-7758            Impact factor:   0.142


  10 in total

1.  Gestational trophoblastic neoplasms (GTNs) do not display epithelial-to-mesenchymal transition (EMT) features.

Authors:  Estelle Dubruc; Fabienne Allias; Anne Pierre Morel; François Golfier; Alain Puisieux; Mojgan Devouassoux-Shisheboran
Journal:  Virchows Arch       Date:  2019-03-08       Impact factor: 4.064

2.  Molecular genetic analysis of placental site trophoblastic tumors and epithelioid trophoblastic tumors confirms their trophoblastic origin.

Authors:  Robert J Oldt; Robert J Kurman; Ie-Ming Shih
Journal:  Am J Pathol       Date:  2002-09       Impact factor: 4.307

3.  Clinicopathologic profile of gestational trophoblastic disease.

Authors:  Darko Jelincic; Gernot Hudelist; Christian Fridolin Singer; Margit Bauer; Lars Christian Horn; Karin Bilek; Klaus Czerwenka
Journal:  Wien Klin Wochenschr       Date:  2003-01-31       Impact factor: 1.704

4.  Expression of c-erbB2 in gestational trophoblastic disease and its clinical significance.

Authors:  Yuxia Wang; Yang Cao; Yongyu Sun
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2002

5.  Immunohistochemistry Study of P53 and C-erbB-2 Expression in Trophoblastic Tissue and Their Predictive Values in Diagnosing Malignant Progression of Simple Molar Pregnancy.

Authors:  Malihe Hasanzadeh; Norrie Sharifi; Marjaneh Farazestanian; Seyed Saman Nazemian; Faezeh Madani Sani
Journal:  Iran J Cancer Prev       Date:  2016-06-13

6.  Coexistence of gastric adenocarcinoma and choriocarcinoma: complete response to trastuzumab and chemotherapy.

Authors:  Seyda Gunduz; Gulsum Ozlem Elpek; Mukremin Uysal; Sema Sezgin Goksu; Murat Tatli; Deniz Arslan; Hasan Senol Coskun; Hakan Bozcuk; Burhan Savas; Mustafa Ozdogan
Journal:  Case Rep Oncol       Date:  2012-07-24

7.  Characterization of apoptosis and autophagy through Bcl-2 and Beclin-1 immunoexpression in gestational trophoblastic disease.

Authors:  Teresa Liliana Wargasetia; Nurhalim Shahib; Djamhoer Martaadisoebrata; Diah Dhianawaty; Bethy Hernowo
Journal:  Iran J Reprod Med       Date:  2015-07

8.  Modulation of wolframin expression in human placenta during pregnancy: comparison among physiological and pathological states.

Authors:  Angela Lucariello; Angelica Perna; Carmine Sellitto; Alfonso Baldi; Alessandro Iannaccone; Luigi Cobellis; Antonio De Luca; Maria De Falco
Journal:  Biomed Res Int       Date:  2014-01-23       Impact factor: 3.411

Review 9.  Autophagy Process in Trophoblast Cells Invasion and Differentiation: Similitude and Differences With Cancer Cells.

Authors:  Lorena Carvajal; Jaime Gutiérrez; Eugenia Morselli; Andrea Leiva
Journal:  Front Oncol       Date:  2021-04-15       Impact factor: 6.244

10.  Epigenetic Dysregulation of Trophoblastic Gene Expression in Gestational Trophoblastic Disease.

Authors:  Zoltan Szabolcsi; Amanda Demeter; Peter Kiraly; Andrea Balogh; Melissa L Wilson; Jennifer R King; Szabolcs Hetey; Zsolt Gelencser; Koji Matsuo; Beata Hargitai; Paulette Mhawech-Fauceglia; Petronella Hupuczi; Andras Szilagyi; Zoltan Papp; Lynda D Roman; Victoria K Cortessis; Nandor Gabor Than
Journal:  Biomedicines       Date:  2021-12-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.